Global Digital Diabetes Management Market - 2025-2033

The global digital diabetes management market reached US$ 14.58 billion in 2024 and is expected to reach US$ 33.26 billion by 2033, growing at a CAGR of 9.7 % during the forecast period of 2025-2033.

The global digital diabetes management market leverages digital technologies, such as devices, software, and services, to improve diabetes management and monitoring. This includes tools like continuous glucose monitors (CGMs), insulin pumps, mobile apps, and cloud-based platforms. These technologies work together to collect, analyze, and share data on a patient's health metrics, providing real-time insights that enable patients and healthcare providers to make informed decisions about diabetes management. The market aims to empower patients to control their glucose levels better, reduce complications, and improve overall health outcomes.

Market Dynamics: Drivers & Restraints

Technological Advancements in Diabetes Digital Health

Technological advancements play a key role in driving the growth of the digital diabetes management market. Innovations such as continuous glucose monitors (CGMs), smart insulin pumps, wearable devices, and AI-powered diabetes management apps are transforming how diabetes is monitored and managed. These technologies provide real-time, personalized data on blood glucose levels, enabling patients and healthcare providers to make better-informed decisions. For instance, AI and big data analytics help refine insulin delivery algorithms and offer individualized treatment recommendations, improving both short- and long-term diabetes management.

Technological advancements are revolutionizing diabetes care by providing effective tools for managing the condition. One key focus is maintaining optimal glucose levels consistently. Digital health tools, including connected insulin pens, portable A1C monitors, and mobile apps, are making it easier for patients to manage their diabetes outside of hospital settings. These mobile applications allow healthcare providers to create personalized treatment plans based on real-time data, ensuring better control over blood glucose levels and potentially reducing long-term health risks.

Another breakthrough in diabetes management is the automated insulin delivery (AID) system, which combines continuous glucose monitors (CGMs) and insulin pumps to automatically adjust insulin levels based on real-time glucose data. This system offers more precise control over blood sugar levels, reducing the burden on patients. Additionally, portable A1C monitors allow individuals to measure their A1C levels at home, providing an essential marker for assessing long-term diabetes control. These advancements contribute significantly to personalized care, enabling patients to better manage their condition with fewer hospital visits.

For instance, in February 2024, Kakao Healthcare launched a new AI-powered diabetes management app called PASTA (Personalized, Accessible, Supportive, Tech-enabled, and Affordable). This app is designed to help people with diabetes and other chronic conditions manage their health more effectively. It integrates with continuous glucose monitoring (CGM) devices, such as i-SENS's CareSens Air and Dexcom's G7, to provide real-time data on blood glucose levels. All these factors demand the global digital diabetes management market.

High Cost of Devices and Technology

The high cost of devices and technology remains a significant restraint in the global digital diabetes management market. Insulin pumps, continuous glucose monitors (CGMs), and other advanced digital tools can be quite expensive, as per National Center for Biotechnology Information (NCBI) data in July 2024, with some insulin pumps costing between $4,500 and $6,500, not including associated consumables. This price tag can be a barrier for patients, especially those without health insurance, limiting their access to essential diabetes management technology.

Moreover, although these devices improve patient outcomes by providing real-time data and better control over glucose levels, studies have shown that insulin pumps may not always be the most cost-effective option compared to multiple daily injections (MDI), especially for those with type 1 diabetes. As a result, the global diabetes management market is expanding rapidly. The above factors are limiting the market growth.

Segment Analysis

The global digital diabetes management market is segmented based on product type, modality, end-user, and region.

Product Type:

The continuous glucose monitoring (CGM) systems segment from product type is expected to dominate the digital diabetes management market with the highest market share

Continuous glucose monitoring (CGM) systems are a major driver of the growth in the global digital diabetes management market. These devices enable patients to monitor their glucose levels in real time throughout the day without the need for frequent fingerstick testing. CGMs provide critical data on glucose fluctuations, offering patients a comprehensive view of their glucose patterns. This real-time data helps individuals with diabetes make more informed decisions about their insulin dosage, diet, and exercise, contributing to better control over blood sugar levels and fewer complications in the long run.

The increasing accuracy, affordability, and convenience of CGMs have significantly boosted their adoption, especially as these devices now integrate with other diabetes management tools, like insulin pumps and mobile apps. Many CGM systems are now more compact, with advanced features such as alarms for high or low glucose levels, and they often work wirelessly with smartphones, providing patients with accessible and personalized management options.

As more people seek non-invasive, continuous monitoring options, CGMs are becoming a key element in both type 1 and type 2 diabetes management. Their widespread use is a major factor driving the expansion of the digital diabetes management market, particularly as healthcare providers leverage data from CGMs to improve treatment outcomes and patient engagement.

For instance, in August 2024, Medtronic announced FDA approval for its Simplera continuous glucose monitor (CGM), marking a significant innovation in diabetes care. Simplera is Medtronic's first all-in-one, disposable CGM that is half the size of its previous models. Designed for simplicity, it features an easy two-step insertion process, making it ideal for individuals using multiple daily insulin injections (MDI).

It eliminates the need for overtape, offering a more discreet and comfortable wear experience. Additionally, the Simplera system integrates seamlessly with the InPen smart insulin pen and is compatible with Medtronic's MiniMed 780G automated insulin delivery system. These factors have solidified the segment's position in the global digital diabetes management market.

Geographical Analysis

North America is expected to hold a significant position in the global digital diabetes management market with the highest market share

The high prevalence of diabetes in the United States, with nearly 16% of adults diagnosed according to the Centers for Disease Control and Prevention (CDC), is a significant driving factor for the growth of the North American digital diabetes management market.

As the number of diabetes cases continues to rise, there is an increasing demand for effective, efficient, and accessible management solutions. Digital health technologies, such as continuous glucose monitoring (CGM) systems, smart insulin pumps, and mobile apps, offer patients real-time data and personalized feedback that can significantly improve diabetes control, reducing complications associated with the disease.

The integration of AI and machine learning into diabetes management devices allows for smarter, more personalized treatment. These technologies help optimize insulin dosing, offer predictive insights, and reduce the frequency of diabetes-related complications. Moreover, the development of wearable devices, such as insulin pumps and glucose sensors, that are more user-friendly and connected to mobile apps enhances patient engagement and self-management.

For instance, in February 2025, Owens & Minor launched the ByramConnect digital health platform, designed to assist individuals with diabetes and other chronic health conditions. This platform is powered by the Welldoc App, which uses artificial intelligence to provide personalized coaching, self-tracking, and clinically relevant insights. It helps individuals manage conditions like type 1 and type 2 diabetes, as well as related conditions such as hypertension, cardiovascular risks, and weight management

Competitive Landscape

The major global players in the digital diabetes management market include Abbott, Dexcom, Inc., F. Hoffmann-La Roche Ltd, Medtronic, and Insulet Corporation. Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG., LifeScan IP Holdings, LLC., AgaMatrix, and Ypsomed AG among others.

Key Developments

• In August 2024, Insulet Corporation's Omnipod 5 Automated Insulin Delivery System was FDA-cleared for use by adults with type 2 diabetes, making it the first and only tubeless automated insulin delivery (AID) system approved for both type 1 and type 2 diabetes management.
• In December 2023, Tandem Diabetes Care launched the full U.S. rollout of its revamped diabetes management platform, Tandem Source. This platform integrates several features from its previous systems, such as t:connect and t:connect HCP, and combines them with enhanced data reporting tools.
• In August 2023, Welldoc, a digital health leader revolutionizing chronic care, announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar. This clearance immediately follows Welldoc's 10th 510(k) clearance announcement earlier this month, solidifying the company's continued leadership in chronic care innovation.
• In August 2023, Nemaura Medical's sugarBEAT received approval from the Saudi Food and Drug Authority (SFDA), marking a significant milestone in the Middle East market. This wearable, non-invasive glucose sensor offers continuous glucose monitoring (CGM) for diabetes and pre-diabetes management.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital diabetes management market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions